zepbound tirzepatide eli lilly F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Eli Lilly's Zepbound Gets FDA

The addition of semaglutide introduces its own set of risks, including gastrointestinal issues like nausea, vomiting, and diarrhea, as well as a potential risk for pancreatitis and gallbladder disease

10.1038/sj.onc.1208940 Oncogene 139 NzouG.WicksR

"Vitamin C"

The Glutathione therapy had no adverse effect on blood chemistries, liver function tests, blood counts

#drugdiscovery #pharma #obesity Great overview of the oral SM GLP-1 landscape worth mentioning though is Structure Therapeutics ($GPCR) and their aleniglipron (GSBR-1290), which is probably the closest structural cousin to orforglipron currently in the clinic

Cons of Adapt Peptides Research Use Only Adapt Peptides supplies compounds strictly for laboratory research